NASDAQ:COLL - Collegium Pharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $25.00
  • Forecasted Upside: 11.16 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$22.49
▲ +0.74 (3.40%)
1 month | 3 months | 12 months
Get New Collegium Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for COLL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COLL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$25.00
▲ +11.16% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Collegium Pharmaceutical in the last 3 months. The average price target is $25.00, with a high forecast of $34.00 and a low forecast of $8.00. The average price target represents a 11.16% upside from the last price of $22.49.
Hold
The current consensus among 4 contributing investment analysts is to hold stock in Collegium Pharmaceutical. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/10/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/8/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/7/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2021HC WainwrightBoost Price TargetBuy$29.00 ➝ $33.00Medium
i
12/29/2020Needham & Company LLCReiterated RatingBuy ➝ BuyN/A
i
Rating by Serge Belanger at Needham & Company LLC
11/9/2020HC WainwrightReiterated RatingBuy$31.00 ➝ $29.00High
i
8/21/2020Needham & Company LLCReiterated RatingBuy$34.00Low
i
Rating by Serge Belanger at Needham & Company LLC
8/14/2020Needham & Company LLCInitiated CoverageBuy$34.00Medium
i
Rating by Serge Belanger at Needham & Company LLC
7/24/2020Needham & Company LLCInitiated CoverageBuy$34.00Medium
i
Rating by Serge Belanger at Needham & Company LLC
7/15/2020Needham & Company LLCReiterated RatingBuy$34.00Low
i
Rating by Serge Belanger at Needham & Company LLC
7/14/2020BWS FinancialInitiated CoverageSell$8.00High
i
Rating by H. Khorsand at BWS Financial
7/6/2020Needham & Company LLCInitiated CoverageBuy$36.00High
i
Rating by Serge Belanger at Needham & Company LLC
6/26/2020Needham & Company LLCInitiated CoverageBuy$36.00High
i
Rating by Serge Belanger at Needham & Company LLC
6/19/2020Needham & Company LLCInitiated CoverageBuy$36.00Medium
i
Rating by Serge Belanger at Needham & Company LLC
6/12/2020Needham & Company LLCInitiated CoverageBuy$36.00Medium
i
Rating by Serge Belanger at Needham & Company LLC
6/5/2020Needham & Company LLCInitiated CoverageBuy$36.00High
i
Rating by Serge Belanger at Needham & Company LLC
5/29/2020Needham & Company LLCInitiated CoverageBuy$36.00High
i
Rating by Serge Belanger at Needham & Company LLC
5/26/2020GuggenheimInitiated CoverageNeutralHigh
i
5/22/2020Needham & Company LLCInitiated CoverageBuy$36.00N/A
i
Rating by Serge Belanger at Needham & Company LLC
5/8/2020Needham & Company LLCLower Price TargetBuy$38.00 ➝ $36.00High
i
Rating by Serge Belanger at Needham & Company LLC
4/24/2020Needham & Company LLCInitiated CoverageBuy$38.00Low
i
Rating by Serge Belanger at Needham & Company LLC
2/28/2020William BlairReiterated RatingBuyMedium
i
Rating by Tim Lugo at William Blair
2/19/2020Jefferies Financial GroupInitiated CoverageBuy$43.00Low
i
2/12/2020Piper SandlerBoost Price TargetOverweight$27.00 ➝ $35.00High
i
Rating by David Amsellem at Piper Sandler
2/7/2020Cantor FitzgeraldBoost Price TargetOverweight$24.00 ➝ $30.00High
i
2/7/2020Needham & Company LLCBoost Price TargetBuy$36.00 ➝ $38.00High
i
Rating by Serge Belanger at Needham & Company LLC
2/4/2020Piper SandlerReiterated RatingBuy$27.00Medium
i
Rating by David Amsellem at Piper Sandler
1/21/2020Needham & Company LLCReiterated RatingBuy$36.00Medium
i
Rating by Serge Belanger at Needham & Company LLC
1/10/2020William BlairReiterated RatingBuyLow
i
Rating by Tim Lugo at William Blair
1/8/2020Needham & Company LLCBoost Price TargetHold$28.00 ➝ $36.00High
i
Rating by Serge Belanger at Needham & Company LLC
1/8/2020HC WainwrightBoost Price TargetBuy ➝ In-Line$25.00 ➝ $29.00High
i
1/6/2020Needham & Company LLCReiterated RatingBuy$28.00N/A
i
Rating by Serge Belanger at Needham & Company LLC
12/30/2019Needham & Company LLCReiterated RatingBuy$28.00Medium
i
Rating by Serge Belanger at Needham & Company LLC
12/23/2019Needham & Company LLCReiterated RatingBuy$28.00Low
i
Rating by Serge Belanger at Needham & Company LLC
12/13/2019Needham & Company LLCReiterated RatingBuy$28.00Low
i
Rating by Serge Belanger at Needham & Company LLC
11/8/2019SunTrust BanksBoost Price TargetBuy$22.00High
i
11/7/2019Jefferies Financial GroupBoost Price Target$26.00 ➝ $36.00High
i
10/30/2019Needham & Company LLCLower Price TargetBuy$33.00 ➝ $25.00Medium
i
Rating by Serge Belanger at Needham & Company LLC
10/18/2019Needham & Company LLCSet Price TargetBuy$33.00Medium
i
Rating by Serge Belanger at Needham & Company LLC
10/11/2019Needham & Company LLCSet Price TargetBuy$33.00Low
i
Rating by Serge Belanger at Needham & Company LLC
9/27/2019Needham & Company LLCSet Price TargetBuy$33.00Medium
i
Rating by Serge Belanger at Needham & Company LLC
9/17/2019William BlairReiterated RatingBuyLow
i
Rating by Tim Lugo at William Blair
8/8/2019Cantor FitzgeraldReiterated RatingPositive ➝ Overweight$35.00 ➝ $24.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
5/3/2019HC WainwrightInitiated CoverageBuy ➝ Buy$23.00Low
i
Rating by O. Livnat at HC Wainwright
4/26/2019Cantor FitzgeraldSet Price TargetBuy$35.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
4/12/2019Cantor FitzgeraldSet Price TargetBuy$35.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
4/12/2019Janney Montgomery ScottInitiated CoverageBuy$29.00High
i
4/5/2019Cantor FitzgeraldSet Price TargetBuy$35.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
3/22/2019Cantor FitzgeraldSet Price TargetBuy$35.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
3/19/2019SunTrust BanksInitiated CoverageHold ➝ Buy$22.00Medium
i
3/8/2019Cantor FitzgeraldSet Price TargetBuy$35.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
2/22/2019Cantor FitzgeraldReiterated RatingBuy$35.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
2/8/2019Cantor FitzgeraldSet Price TargetBuy$35.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
1/25/2019Cantor FitzgeraldSet Price TargetBuy$35.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
1/16/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00 ➝ $33.00Low
i
1/7/2019Cantor FitzgeraldReiterated RatingBuy$35.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
11/30/2018Cantor FitzgeraldSet Price TargetBuy$35.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
11/8/2018Cantor FitzgeraldReiterated RatingBuy$35.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
10/24/2018Cantor FitzgeraldSet Price TargetBuy$35.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
9/21/2018Cantor FitzgeraldSet Price TargetBuy$35.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
9/17/2018HC WainwrightReiterated RatingBuyHigh
i
Rating by E. Arce at HC Wainwright
8/9/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.00High
i
Rating by J. Foresi at Cantor Fitzgerald
8/6/2018Janney Montgomery ScottSet Price TargetBuy$27.00Low
i
Rating by Ken Trbovich at Janney Montgomery Scott
7/11/2018Piper Jaffray CompaniesSet Price TargetBuy$34.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
6/20/2018Cantor FitzgeraldReiterated RatingBuy$40.00Low
i
Rating by J. Foresi at Cantor Fitzgerald
6/14/2018Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by J. Foresi at Cantor Fitzgerald
6/11/2018Cantor FitzgeraldInitiated CoverageBuy$40.00High
i
3/8/2018William BlairReiterated RatingOutperformHigh
i
3/8/2018HC WainwrightBoost Price TargetBuy ➝ Buy$21.00 ➝ $33.00High
i
Rating by E. Arce at HC Wainwright
2/12/2018Jefferies Financial GroupBoost Price TargetBuy$32.00Low
i
2/12/2018Piper Jaffray CompaniesSet Price TargetBuy$33.00High
i
Rating by David Amsellem at Piper Jaffray Companies
2/7/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$28.00 ➝ $35.00Low
i
2/6/2018Janney Montgomery ScottSet Price TargetBuy ➝ Buy$21.00 ➝ $26.00Low
i
1/23/2018Piper Jaffray CompaniesSet Price TargetBuy$33.00High
i
Rating by David Amsellem at Piper Jaffray Companies
12/14/2017Piper Jaffray CompaniesSet Price TargetBuy$23.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
12/7/2017Piper Jaffray CompaniesReiterated RatingBuy$24.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
12/5/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$25.00 ➝ $28.00High
i
Rating by Serge Belanger at Needham & Company LLC
12/5/2017Jefferies Financial GroupBoost Price TargetBuy$27.00High
i
11/29/2017Piper Jaffray CompaniesSet Price TargetBuy$19.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
11/17/2017HC WainwrightReiterated RatingBuy$21.00N/A
i
Rating by E. Arce at HC Wainwright
11/8/2017HC WainwrightReiterated RatingBuy$21.00N/A
i
Rating by E. Arce at HC Wainwright
10/6/2017Needham & Company LLCReiterated RatingBuy$25.00N/A
i
Rating by Serge Belanger at Needham & Company LLC
10/6/2017Jefferies Financial GroupReiterated RatingBuy$15.00N/A
i
9/21/2017Jefferies Financial GroupReiterated RatingBuy$15.00High
i
Rating by David Steinberg at Jefferies Financial Group Inc.
9/11/2017HC WainwrightInitiated CoverageBuy ➝ Buy$21.00High
i
Rating by E. Arce at HC Wainwright
9/8/2017Piper Jaffray CompaniesReiterated RatingBuy$14.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
7/25/2017Piper Jaffray CompaniesSet Price TargetBuy$14.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
6/12/2017Janney Montgomery ScottReiterated RatingBuy$25.00Medium
i
6/9/2017Needham & Company LLCReiterated RatingBuy$25.00Low
i
5/31/2017Needham & Company LLCReiterated RatingBuy$25.00Low
i
5/11/2017Jefferies Financial GroupReiterated RatingBuy$24.00 ➝ $22.00Low
i
Rating by David Steinberg at Jefferies Financial Group Inc.
5/11/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$28.00 ➝ $25.00High
i
4/19/2017Needham & Company LLCReiterated RatingBuy$30.00 ➝ $28.00Low
i
3/25/2017Jefferies Financial GroupSet Price TargetBuy$24.00Low
i
Rating by David Steinberg at Jefferies Financial Group Inc.
11/11/2016Jefferies Financial GroupReiterated RatingBuy$27.00 ➝ $24.00N/A
i
10/12/2016Piper Jaffray CompaniesSet Price TargetBuy$23.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
9/22/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
9/14/2016Needham & Company LLCReiterated RatingBuy$30.00N/A
i
9/13/2016GabelliInitiated CoverageBuy$25.00N/A
i
Rating by K. Kedra at Gabelli
8/11/2016Piper Jaffray CompaniesSet Price TargetBuy$27.00 ➝ $23.00N/A
i
Rating by david amsellem at Piper Jaffray Companies
6/23/2016Piper Jaffray CompaniesReiterated RatingBuy$26.00 ➝ $27.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
5/26/2016Needham & Company LLCReiterated RatingBuy$28.00 ➝ $30.00N/A
i
5/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/A
i
3/15/2016Janney Montgomery ScottInitiated CoverageBuy$25.00N/A
i
(Data available from 3/7/2016 forward)
Collegium Pharmaceutical logo
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Read More

Today's Range

Now: $22.49
$21.36
$22.61

50 Day Range

MA: $24.14
$21.75
$26.10

52 Week Range

Now: $22.49
$13.00
$26.91

Volume

385,410 shs

Average Volume

737,721 shs

Market Capitalization

$781.66 million

P/E Ratio

45.90

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Collegium Pharmaceutical?

The following Wall Street sell-side analysts have issued stock ratings on Collegium Pharmaceutical in the last year: BWS Financial, Guggenheim, HC Wainwright, Needham & Company LLC, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for COLL.

What is the current price target for Collegium Pharmaceutical?

3 Wall Street analysts have set twelve-month price targets for Collegium Pharmaceutical in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 11.2%. Needham & Company LLC has the highest price target set, predicting COLL will reach $34.00 in the next twelve months. BWS Financial has the lowest price target set, forecasting a price of $8.00 for Collegium Pharmaceutical in the next year.
View the latest price targets for COLL.

What is the current consensus analyst rating for Collegium Pharmaceutical?

Collegium Pharmaceutical currently has 1 sell rating, 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in COLL, but not buy more shares or sell existing shares.
View the latest ratings for COLL.

What other companies compete with Collegium Pharmaceutical?

How do I contact Collegium Pharmaceutical's investor relations team?

Collegium Pharmaceutical's physical mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company's listed phone number is 781-713-3699. The official website for Collegium Pharmaceutical is www.collegiumpharma.com.